These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33920489)

  • 1. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.
    Pappa V; Bouchla A; Terpos E; Thomopoulos TP; Rosati M; Stellas D; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Kotanidou A; Kalomenidis I; Poulakou G; Jahaj E; Korompoki E; Grigoropoulou S; Hu X; Bear J; Karaliota S; Burns R; Pagoni M; Trontzas I; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Felber BK; Pavlakis GN; Dimopoulos MA
    Microorganisms; 2021 Apr; 9(4):. PubMed ID: 33920489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study.
    Albalawi M; Zaidi SZA; AlShehry N; AlAskar A; Zaidi ARZ; Abdallah RNM; Salam A; AlSagheir A; AlMozain N; Elgohary G; Batarfi K; Alfaraedi A; Khojah O; Al-Ansari R; Alfaraj M; Dayel A; Al Bahrani A; Abdelhameed AN; Alhumaidan H; Al-Otaibi JM; Radwi G; Raizah A; Shatry H; Alsaleh S; AlZahrani H; Al-Hashmi H
    JMIR Res Protoc; 2020 Oct; 9(10):e23543. PubMed ID: 32903199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.
    AlShehry N; Zaidi SZA; AlAskar A; Al Odayani A; Alotaibi JM; AlSagheir A; Al-Eyadhy A; Balelah S; Salam A; Zaidi ARZ; Alawami D; Alshahrani MS; AlMozain N; Abulhamayel YM; Al Qunfoidi R; Alfaraj M; Qushmaq N; Alansari R; Dayel A; Elgohary G; Al Bahrani A; Nabhan Abdelhameed AA; AlZahrani HA; Alturkistani H; AlShehry N; Albalawi MA; Elalfy I; Alhumaidan H; Al-Hashmi H;
    Saudi J Med Med Sci; 2021; 9(1):16-23. PubMed ID: 33519339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study.
    Abuzakouk M; Saleh K; Algora M; Nusair A; Alameri J; Alshehhi F; Alkhaja S; Badr M; Abdallah K; De Oliveira B; Nadeem A; Varghese Y; Munde D; Salam S; Abduljawad B; Elkambergy H; Wahla A; Taha A; Dibu J; Bayrlee A; Hamed F; AbdelWareth L; Rahman N; Guzman J; Mallat J
    J Clin Med; 2021 May; 10(10):. PubMed ID: 34068847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial.
    Ventura-Enríquez Y; Cabello-Gutiérrez C; Pérez-Calatayud ÁA; Cortina-De la Rosa E; Fareli-González CJ; Castillo-Juárez P; Carlos AP; Zavaleta-Martínez EO; Diaz-Padilla E; Murrieta S; Álvarez-Jiménez VD; Ponce-Medrano JAD; Casillas-Suárez C; Ocampo-Ocampo MA; Vargas-De-León C; Fernández-Sánchez V
    Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36362922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.
    Barreira DF; Lourenço RA; Calisto R; Moreira-Gonçalves D; Santos LL; Videira PA
    Front Med (Lausanne); 2021; 8():660688. PubMed ID: 33889590
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study.
    Kurtz P; Righy C; Gadelha M; Bozza FA; Bozza PT; Gonçalves B; Bastos LSL; Vale AM; Higa LM; Castilho L; Monteiro FL; Charris N; Fialho F; Turon R; Guterres A; Lyra Miranda R; de Azeredo Lima CH; de Caro V; Prazeres MA; Ventura N; Gaspari C; Miranda F; Jose da Mata P; Pêcego M; Mateos S; Lopes ME; Castilho S; Oliveira Á; Boquimpani C; Rabello A; Lopes J; Neto OC; Ferreira ODC; Tanuri A; Filho PN; Amorim L
    Front Med (Lausanne); 2021; 8():630982. PubMed ID: 33585529
    [No Abstract]   [Full Text] [Related]  

  • 8. Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases.
    Thijssen M; Devos T; Ejtahed HS; Amini-Bavil-Olyaee S; Pourfathollah AA; Pourkarim MR
    Microorganisms; 2020 Nov; 8(11):. PubMed ID: 33167389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.
    Bansal V; Mahapure KS; Mehra I; Bhurwal A; Tekin A; Singh R; Gupta I; Rathore SS; Khan H; Deshpande S; Gulati S; Armaly P; Sheraton M; Kashyap R
    Front Med (Lausanne); 2021; 8():624924. PubMed ID: 33898477
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience.
    Joyner MJ; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Carter RE; Casadevall A
    medRxiv; 2020 Aug; ():. PubMed ID: 32817978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent plasma appears efficacious and safe in COVID-19.
    Khulood D; Adil MS; Sultana R; Nimra
    Ther Adv Infect Dis; 2020; 7():2049936120957931. PubMed ID: 33062267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of convalescent plasma therapy in eight individuals with mild COVID-19.
    Ji F; Liu W; Hao DA; Cheng J; Tong XC; Hao JG; Wang LP; Li CY; Dai MJ; Yan XB
    New Microbes New Infect; 2021 Jan; 39():100814. PubMed ID: 33204428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients.
    Liu C; Yu X; Gao C; Zhang L; Zhai H; Hu Y; Liu E; Wang Q; Gao Y; Wei D; Zhang D; Han Y; Zhang X
    J Med Virol; 2021 Apr; 93(4):2227-2233. PubMed ID: 33135795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
    Beaudoin-Bussières G; Laumaea A; Anand SP; Prévost J; Gasser R; Goyette G; Medjahed H; Perreault J; Tremblay T; Lewin A; Gokool L; Morrisseau C; Bégin P; Tremblay C; Martel-Laferrière V; Kaufmann DE; Richard J; Bazin R; Finzi A
    mBio; 2020 Oct; 11(5):. PubMed ID: 33067385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia.
    Peppers BP; Shmookler A; Stanley J; Giblin Sutton L; Perrotta PL; Kieffer T; Skoner D; Mahady S; Lewandrowski C; Damron H; Horspool A; Sakhjua A; McCarthy P; Hostoffer RW
    Allergy Rhinol (Providence); 2022; 13():21526575221110488. PubMed ID: 35795339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of time and titer in convalescent plasma therapy for COVID-19.
    de Candia P; Prattichizzo F; Garavelli S; La Grotta R; De Rosa A; Pontarelli A; Parrella R; Ceriello A; Matarese G
    iScience; 2021 Aug; 24(8):102898. PubMed ID: 34316549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential predictors of outcomes among hospitalized COVID-19 patients treated with convalescent plasma: a single-center study.
    Chilimuri S; Zahid M; Mantri N; Sun H; Saleh M; Ashraf S; Gongati S; Adrish M
    J Community Hosp Intern Med Perspect; 2021 Jun; 11(4):464-469. PubMed ID: 34211649
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.
    O'Donnell MR; Grinsztejn B; Cummings MJ; Justman JE; Lamb MR; Eckhardt CM; Philip NM; Cheung YK; Gupta V; João E; Pilotto JH; Diniz MP; Cardoso SW; Abrams D; Rajagopalan KN; Borden SE; Wolf A; Sidi LC; Vizzoni A; Veloso VG; Bitan ZC; Scotto DE; Meyer BJ; Jacobson SD; Kantor A; Mishra N; Chauhan LV; Stone EF; Dei Zotti F; La Carpia F; Hudson KE; Ferrara SA; Schwartz J; Stotler BA; Lin WW; Wontakal SN; Shaz B; Briese T; Hod EA; Spitalnik SL; Eisenberger A; Lipkin WI
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33974559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.
    Klassen SA; Senefeld JW; Johnson PW; Carter RE; Wiggins CC; Shoham S; Grossman BJ; Henderson JP; Musser J; Salazar E; Hartman WR; Bouvier NM; Liu STH; Pirofski LA; Baker SE; van Helmond N; Wright RS; Fairweather D; Bruno KA; Wang Z; Paneth NS; Casadevall A; Joyner MJ
    Mayo Clin Proc; 2021 May; 96(5):1262-1275. PubMed ID: 33958057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.
    Camou F; Tinevez C; Beguet-Yachine M; Bellecave P; Ratiarison D; Tumiotto C; Lafarge X; Guisset O; Mourissoux G; Lafon ME; Bonnet F; Issa N
    J Med Virol; 2021 Sep; 93(9):5594-5598. PubMed ID: 33942327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.